Relmada Therapeutics, Inc. (RLMD) P/E Ratio History
Historical price-to-earnings valuation from 2015 to 2016
Loading P/E history...
RLMD Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Relmada Therapeutics, Inc. (RLMD) trades at a price-to-earnings ratio of -5.1x, with a stock price of $7.43 and trailing twelve-month earnings per share of $-0.84.
The current P/E is 701% below its 5-year average of 0.9x. Over the past five years, RLMD's P/E has ranged from a low of 0.6x to a high of 1.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, RLMD trades at a 123% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, RLMD trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RLMD DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
RLMD P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $351M | 28.4 | - | +120% | |
| $2B | 6.9Lowest | 0.67 | +817%Best | |
| $4B | 9.9 | - | +68% | |
| $3B | 11.4 | 0.07Best | +40% | |
| $30B | 22.8 | 0.56 | +5% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
RLMD Historical P/E Data (2015–2016)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2016 Q1 | $1.36 | $2.21 | 0.6x | -28% | |
| FY2015 Q4 | $2.00 | $1.91 | 1.0x | +23% | |
| FY2015 Q3 | Wed Sep 30 2015 00:00:00 GM | $3.92 | $4.37 | 0.9x | +5% |
Average P/E for displayed period: 0.9x
See RLMD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RLMD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RLMD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRLMD — Frequently Asked Questions
Quick answers to the most common questions about buying RLMD stock.
Is RLMD stock overvalued or undervalued?
RLMD trades at -5.1x P/E, below its 5-year average of 0.9x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does RLMD's valuation compare to peers?
Relmada Therapeutics, Inc. P/E of -5.1x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is RLMD's PEG ratio?
RLMD PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2015-2016.